VTRS

Viatris Inc

NasdaqAdd to watchlist

Healthcare · Drug Manufacturers—Specialty & Generic

$16.88

−$0.06−0.35%

Delayed · 2026-09-04T20:00:00.000Z · marketstack

3 of 47tracked managers hold this· Q2 2026

Aug 10, 2026$16.88

+$0.60+3.69%over 1M

Day range60% of range

$16.67$17.02

Session

Previous close: $16.94
Open: $16.81
Volume: 5.73M
Avg volume: -
Day high: $17.02
Day low: $16.67

Fundamentals

Visualize fundamentals and more

Market cap: 19.64B
P/E ratio: -
EPS (TTM): -
Dividend yield: -
Beta: 0.87
Shares outstanding: 1.16B

Source SEC EDGAR · 9/10/2026

Tracked investors

As of Q2 2026 · 72 days ago · next update ~14 Nov 2026· what moved this quarter, onMeasure

3 fund managers this platform follows disclosed a position here, from quarterly SEC filings up to 45 days old; a manager may have sold since without yet having to say so.

Joel Greenblatt
Gotham Asset Management
$69.47M
0.16%of book
David Einhorn
Greenlight Capital
$44.04M
1.13%of book

1 more holder, included withMeasure

Manager	Position	Share of their book	Last change
Joel Greenblatt Gotham Asset Management	$69.47M	0.16%
David Einhorn Greenlight Capital	$44.04M	1.13%

1 more holder, included withMeasure

Share price, with each quarter a tracked manager’s position changed shaded across the range it traded in.

81216

now

Q3 '24

Q4 '24

Q1 '25

Q2 '25

Q3 '25

Q4 '25

Q1 '26

Q2 '26

Hover a shaded quarter to see it moved. Who, and the range they traded in, is onBespoke

1 further quarter with a tracked move is not shaded here, because this platform holds no share prices for it yet.

13F filings cover US-listed shares only (not cash, bonds, shorts, or private holdings) and are never a recommendation to do the same.

Risk factors, year on year

Item 1AFebruary 2026 10-KFebruary 2025as filed.

added: 51
dropped: 41
re-drafted: 43

Out of 253 passages in this year’s Item 1A.

New this year

◦ Viatris’ restructuring activities may not achieve their intended goals and may present significant challenges, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends or …

91 more passages, included withBespoke

Recent activity

3 more events, included withMeasure

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Companies like Viatris Inc

Also filed under Drug Manufacturers, ranked by how closely they sit beside VTRS.

LLYELI LILLY & Co
JNJJOHNSON & JOHNSON
AMGNAMGEN INC
MRKMerck & Co., Inc.
ABBVAbbVie Inc.
PFEPFIZER INC

Ask about Viatris Inc

The assistant answers from what VTRS has actually filed: 8 annual reports filed with the SEC, 13F positions from the 3 tracked investors who hold it and 6 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Pressing one answers it here, from VTRS's filings and figures. One a day without an account; a free account has its own, and no card.

See every investor holding Viatris Inc, and every quarter they moved.

Ten seconds, no card, and nothing to cancel.

What an account lets you do with Viatris Inc

Separate the decisions from the paperwork
Every Form 4 VTRS insiders have filed, with vesting and automatic tax sales struck out: what's left is the buys and sells somebody actually chose to make.
Every filingMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: who added, who trimmed, who walked away.
Every position they holdMeasure
Interrogate the filing, not the internet
Ask anything about Viatris Inc's fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free accountSee what the paid plans add

Free, no card, and it does not expire.